Atrium Therapeutics Issues Inducement Grants to New Hire
San Diego-based Atrium Therapeutics has granted stock options and restricted stock units to a newly hired non-executive employee. Approved by the company's independent Human Capital Management Committee, the awards function as a material inducement for employment under the firm's 2026 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4).
The employee received non-qualified stock options to purchase 11,000 shares at an exercise price of $13.48 per share, matching the Nasdaq closing price on August 20. Vesting for these options begins with 25% on the first anniversary, followed by 36 monthly installments. Additionally, the grant includes 5,500 restricted stock units, which vest 25% after one year with the remainder distributed over three subsequent annual installments, contingent upon continued service.
Atrium Therapeutics, which trades under the ticker RNA, currently focuses on precision cardiology. The company is advancing its ATR 1072 program for PRKAG2 syndrome into the Corventis Phase 1/2 clinical trial following recent FDA clearance. Their pipeline utilizes proprietary technology designed to deliver small interfering RNA to the heart, aiming to address the drivers of genetically linked cardiomyopathies.
Comments (0)
No comments yet. Be the first!